Company & Sponsor Intelligence

Annovis Bio Inc.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting1

Completed2

Countries1

Therapeutic footprint

alzheimersparkinsons

Indexed studies

NCT05357989A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
parkinsons · United StatesPHASE3

NCT04524351Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients
alzheimers · United StatesPHASE1, PHASE2

NCT07284784A Study of Buntanetap in Participants With PD
parkinsons · United StatesPHASE2, PHASE3

Intelligence layer updated: 2026-10-31 06:16:59.340585+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →